

# Eric C Strain

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1668603/publications.pdf>

Version: 2024-02-01

157  
papers

8,300  
citations

53794

45  
h-index

49909

87  
g-index

162  
all docs

162  
docs citations

162  
times ranked

6486  
citing authors

#	ARTICLE	IF	CITATIONS
1	Caffeinated energy drinks—A growing problem. <i>Drug and Alcohol Dependence</i> , 2009, 99, 1-10.	3.2	791
2	A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence. <i>New England Journal of Medicine</i> , 2000, 343, 1290-1297.	27.0	596
3	Withdrawal Syndrome after the Double-Blind Cessation of Caffeine Consumption. <i>New England Journal of Medicine</i> , 1992, 327, 1109-1114.	27.0	388
4	Moderate- vs High-Dose Methadone in the Treatment of Opioid Dependence. <i>JAMA - Journal of the American Medical Association</i> , 1999, 281, 1000.	7.4	378
5	Modulation of cellular immunity in medical students. <i>Journal of Behavioral Medicine</i> , 1986, 9, 5-21.	2.1	363
6	Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. <i>Psychopharmacology</i> , 2001, 157, 151-162.	3.1	221
7	A Double-Blind, Placebo-Controlled Trial Assessing the Efficacy of Varenicline Tartrate for Alcohol Dependence. <i>Journal of Addiction Medicine</i> , 2013, 7, 277-286.	2.6	220
8	Buprenorphine: how to use it right. <i>Drug and Alcohol Dependence</i> , 2003, 70, S59-S77.	3.2	214
9	Methadone Safety: A Clinical Practice Guideline From the American Pain Society and College on Problems of Drug Dependence, in Collaboration With the Heart Rhythm Society. <i>Journal of Pain</i> , 2014, 15, 321-337.	1.4	203
10	Dose-Response Effects of Methadone in the Treatment of Opioid Dependence. <i>Annals of Internal Medicine</i> , 1993, 119, 23.	3.9	198
11	A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. <i>Drug and Alcohol Dependence</i> , 1995, 40, 17-25.	3.2	179
12	Effects of buprenorphine/naloxone in opioid-dependent humans. <i>Psychopharmacology</i> , 2001, 154, 230-242.	3.1	150
13	Site of Opioid Action in the Human Brain: Mu and Kappa Agonists' Subjective and Cerebral Blood Flow Effects. <i>American Journal of Psychiatry</i> , 1998, 155, 470-473.	7.2	137
14	Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. <i>Drug and Alcohol Dependence</i> , 2009, 105, 154-159.	3.2	128
15	A Liquid Chromatographic-Electrospray Ionization-Tandem Mass Spectrometric Method for Determination of Buprenorphine, Its Metabolite, norBuprenorphine, and a Coformulant, Naloxone, That Is Suitable for in Vivo and in Vitro Metabolism Studies. <i>Analytical Biochemistry</i> , 2002, 306, 31-39.	2.4	124
16	Buprenorphine Versus Methadone in the Treatment of Opioid Dependence. <i>Journal of Clinical Psychopharmacology</i> , 1996, 16, 58-67.	1.4	115
17	Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. <i>Psychopharmacology</i> , 1994, 116, 401-406.	3.1	110
18	Methadone dose and treatment outcome. <i>Drug and Alcohol Dependence</i> , 1993, 33, 105-117.	3.2	106

#	ARTICLE	IF	CITATIONS
19	Assessment and Treatment of Comorbid Psychiatric Disorders in Opioid-Dependent Patients. <i>Clinical Journal of Pain</i> , 2002, 18, S14-S27.	1.9	105
20	Service Use and Barriers to Mental Health Care Among Adults With Major Depression and Comorbid Substance Dependence. <i>Psychiatric Services</i> , 2013, 64, 863-870.	2.0	101
21	Decreased frontal white-matter volume in chronic substance abuse. <i>International Journal of Neuropsychopharmacology</i> , 2006, 9, 147.	2.1	94
22	Gender Differences in Substance Abuse Treatment and Barriers to Care Among Persons With Substance Use Disorders With and Without Comorbid Major Depression. <i>Journal of Addiction Medicine</i> , 2013, 7, 325-334.	2.6	94
23	Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. <i>Drug and Alcohol Dependence</i> , 1995, 40, 27-35.	3.2	89
24	Intravenous drug abusers with antisocial personality disorder: increased HIV risk behavior. <i>Drug and Alcohol Dependence</i> , 1990, 26, 39-44.	3.2	88
25	Characteristics of older opioid maintenance patients. <i>Journal of Substance Abuse Treatment</i> , 2005, 28, 265-272.	2.8	86
26	Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. <i>Drug and Alcohol Dependence</i> , 2007, 90, 261-269.	3.2	85
27	A hidden aspect of the U.S. opioid crisis: Rise in first-time treatment admissions for older adults with opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2018, 193, 142-147.	3.2	80
28	A randomized controlled trial of the effects of working memory training in methadone maintenance patients. <i>Drug and Alcohol Dependence</i> , 2015, 156, 38-46.	3.2	79
29	Changing Profile of Abused Substances by Older Persons Entering Treatment. <i>Journal of Nervous and Mental Disease</i> , 2008, 196, 898-905.	1.0	74
30	Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. <i>Drug and Alcohol Dependence</i> , 2004, 74, 37-43.	3.2	68
31	Pretreatment Alcohol Drinking Goals are Associated with Treatment Outcomes. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 1745-1752.	2.4	68
32	Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence.. <i>Experimental and Clinical Psychopharmacology</i> , 2005, 13, 293-302.	1.8	63
33	Treatment of patients with substance use disorders, second edition. American Psychiatric Association. <i>American Journal of Psychiatry</i> , 2006, 163, 5-82.	7.2	62
34	A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence. <i>Neuropsychopharmacology</i> , 2017, 42, 1012-1023.	5.4	61
35	Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 158-169.	2.4	60
36	Physical dependence potential of daily tramadol dosing in humans. <i>Psychopharmacology</i> , 2010, 211, 457-466.	3.1	59

#	ARTICLE	IF	CITATIONS
37	Prescriptions, Nonmedical Use, and Emergency Department Visits Involving Prescription Stimulants. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e297-e304.	2.2	59
38	Clustering of multiple substance use and psychiatric diagnoses in opiate addicts. <i>Drug and Alcohol Dependence</i> , 1991, 27, 127-134.	3.2	56
39	What defines a clinically meaningful outcome in the treatment of substance use disorders: reductions in direct consequences of drug use or improvement in overall functioning?. <i>Addiction</i> , 2019, 114, 9-15.	3.3	56
40	Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone. <i>American Journal on Addictions</i> , 2021, 30, 83-87.	1.4	56
41	The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: A review. <i>Drug and Alcohol Dependence</i> , 2011, 119, 1-9.	3.2	53
42	Voucher-based reinforcement of opiate abstinence during methadone detoxification. <i>Drug and Alcohol Dependence</i> , 2002, 65, 179-189.	3.2	52
43	Measures of outcome for stimulant trials: ACTION recommendations and research agenda. <i>Drug and Alcohol Dependence</i> , 2016, 158, 1-7.	3.2	49
44	Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients. <i>Addictive Behaviors</i> , 2018, 76, 8-14.	3.0	49
45	The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. <i>Drug and Alcohol Dependence</i> , 2020, 212, 107993.	3.2	49
46	Protracted renal clearance of fentanyl in persons with opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2020, 214, 108147.	3.2	49
47	Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: Development and pilot test of a clinical protocol. <i>Journal of Opioid Management</i> , 2012, 8, 369-82.	0.5	48
48	Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. <i>Psychopharmacology</i> , 2002, 159, 161-166.	3.1	47
49	Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone Soluble-Films. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 443-449.	4.7	45
50	Modest opioid withdrawal suppression efficacy of oral tramadol in humans. <i>Psychopharmacology</i> , 2007, 194, 381-393.	3.1	44
51	Topiramate for cocaine dependence during methadone maintenance treatment: A randomized controlled trial. <i>Drug and Alcohol Dependence</i> , 2014, 140, 92-100.	3.2	43
52	Efficacy of Tramadol Extended-Release for Opioid Withdrawal. <i>JAMA Psychiatry</i> , 2017, 74, 885.	11.0	42
53	Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. <i>Drug and Alcohol Dependence</i> , 1997, 45, 81-91.	3.2	41
54	A Double-Blind, Placebo-Controlled Trial Assessing the Efficacy of Levetiracetam Extended-Release in Very Heavy Drinking Alcohol-Dependent Patients. <i>Alcoholism: Clinical and Experimental Research</i> , 2012, 36, 1421-1430.	2.4	41

#	ARTICLE	IF	CITATIONS
55	Correlates of nonmedical use of stimulants and methamphetamine use in a national sample. <i>Addictive Behaviors</i> , 2014, 39, 829-836.	3.0	41
56	Characterizing pain and associated coping strategies in methadone and buprenorphine-maintained patients. <i>Drug and Alcohol Dependence</i> , 2015, 157, 143-149.	3.2	41
57	A randomized controlled trial of fluoxetine in the treatment of cocaine dependence among methadone-maintained patients. <i>Journal of Substance Abuse Treatment</i> , 2011, 40, 255-264.	2.8	40
58	Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder. <i>Drug and Alcohol Dependence</i> , 2019, 194, 500-517.	3.2	39
59	A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers. <i>Drug and Alcohol Dependence</i> , 2004, 74, 205-209.	3.2	38
60	Simultaneous determination of buprenorphine, norbuprenorphine and the enantiomers of methadone and its metabolite (EDDP) in human plasma by liquid chromatography/mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 850, 538-543.	2.3	36
61	Discriminative Stimulus Effects of Tramadol in Humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 338, 255-262.	2.5	36
62	An fMRI Investigation of Cerebellar Function During Verbal Working Memory in Methadone Maintenance Patients. <i>Cerebellum</i> , 2012, 11, 300-310.	2.5	34
63	A Systematic Review of Laboratory Evidence for the Abuse Potential of Tramadol in Humans. <i>Frontiers in Psychiatry</i> , 2019, 10, 704.	2.6	34
64	A Double Blind, within Subject Comparison of Spontaneous Opioid Withdrawal from Buprenorphine versus Morphine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 348, 217-226.	2.5	32
65	Effects of repeated tramadol and morphine administration on psychomotor and cognitive performance in opioid-dependent volunteers. <i>Drug and Alcohol Dependence</i> , 2010, 111, 265-268.	3.2	31
66	Craving and opioid use disorder: A scoping review. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107639.	3.2	31
67	HIV risk behaviors during pharmacologic treatment for opioid dependence: A comparison of levomethadyl acetate hydrochloride, buprenorphine, and methadone. <i>Journal of Substance Abuse Treatment</i> , 2006, 31, 187-194.	2.8	30
68	Increased Blood Pressure After Abrupt Cessation of Daily Cannabis Use. <i>Journal of Addiction Medicine</i> , 2011, 5, 16-20.	2.6	30
69	Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes. <i>Addiction Biology</i> , 2020, 25, e12680.	2.6	30
70	Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans. <i>Addiction</i> , 2003, 98, 427-439.	3.3	27
71	Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone. <i>Psychopharmacology</i> , 2010, 210, 471-480.	3.1	27
72	Instruments to Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: An ACTION Systematic Review. <i>Journal of Pain</i> , 2015, 16, 389-411.	1.4	26

#	ARTICLE	IF	CITATIONS
73	Cognitive performance in methadone maintenance patients: Effects of time relative to dosing and maintenance dose level.. <i>Experimental and Clinical Psychopharmacology</i> , 2014, 22, 248-256.	1.8	25
74	Outpatient Treatment Entry and Health Care Utilization After a Combined Medical/Substance Abuse Intervention for Hospitalized Medical Patients. <i>Journal of General Internal Medicine</i> , 2002, 17, 334-340.	2.6	24
75	Temporal preference in individuals reporting chronic pain: discounting of delayed pain-related and monetary outcomes. <i>Pain</i> , 2016, 157, 1724-1732.	4.2	23
76	Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	23
77	The therapeutic workplace to promote treatment engagement and drug abstinence in out-of-treatment injection drug users: A randomized controlled trial. <i>Preventive Medicine</i> , 2014, 68, 62-70.	3.4	22
78	Relationship between cannabis use frequency and major depressive disorder in adolescents: Findings from the National Survey on Drug Use and Health 2012-2017. <i>Drug and Alcohol Dependence</i> , 2020, 208, 107867.	3.2	22
79	Relationship between Cigarette Use and Mood/Anxiety Disorders among Pregnant Methadone-Maintained Patients. <i>American Journal on Addictions</i> , 2009, 18, 422-429.	1.4	22
80	Outcome after methadone treatment: influence of prior treatment factors and current treatment status. <i>Drug and Alcohol Dependence</i> , 1994, 35, 223-230.	3.2	21
81	Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period. <i>Psychopharmacology</i> , 2006, 189, 297-306.	3.1	21
82	Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers. <i>Psychopharmacology</i> , 2010, 211, 303-312.	3.1	21
83	Patterns of concurrent substance use among nonmedical ADHD stimulant users: Results from the National Survey on Drug Use and Health. <i>Drug and Alcohol Dependence</i> , 2014, 142, 86-90.	3.2	20
84	Research approaches for evaluating opioid sparing in clinical trials of acute and chronic pain treatments: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials recommendations. <i>Pain</i> , 2021, 162, 2669-2681.	4.2	20
85	Experimental sleep disruption attenuates morphine analgesia: findings from a randomized trial and implications for the opioid abuse epidemic. <i>Scientific Reports</i> , 2020, 10, 20121.	3.3	19
86	Gradual Dose Taper Following Chronic Buprenorphine. <i>American Journal on Addictions</i> , 2001, 10, 111-121.	1.4	18
87	Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans.. <i>Experimental and Clinical Psychopharmacology</i> , 2006, 14, 109-120.	1.8	18
88	Cigarette smoking knowledge, attitudes, and practices of patients and staff at a perinatal substance abuse treatment center. <i>Journal of Substance Abuse Treatment</i> , 2010, 39, 298-305.	2.8	18
89	Employment-based abstinence reinforcement promotes opiate and cocaine abstinence in out-of-treatment injection drug users. <i>Journal of Applied Behavior Analysis</i> , 2014, 47, 681-693.	2.7	18
90	Opioid antagonist effects of dezocine in opioid-dependent humans*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 206-217.	4.7	17

#	ARTICLE	IF	CITATIONS
91	Safety and Efficacy of L-tryptophan and Behavioral Incentives for Treatment of Cocaine Dependence: A Randomized Clinical Trial. <i>American Journal on Addictions</i> , 2004, 13, 421-437.	1.4	16
92	Sources of nonmedically used prescription stimulants: Differences in onset, recency and severity of misuse in a population-based study. <i>Drug and Alcohol Dependence</i> , 2014, 145, 106-112.	3.2	16
93	Patterns of concurrent substance use among adolescent nonmedical ADHD stimulant users. <i>Addictive Behaviors</i> , 2015, 49, 1-6.	3.0	16
94	Time to Reconsider the Role of Craving in Opioid Use Disorder. <i>JAMA Psychiatry</i> , 2019, 76, 1113.	11.0	16
95	Classifying substance use disorder treatment facilities with co-located mental health services: A latent class analysis approach. <i>Drug and Alcohol Dependence</i> , 2016, 163, 108-115.	3.2	15
96	Analgesic Effects of Hydromorphone versus Buprenorphine in Buprenorphine-maintained Individuals. <i>Anesthesiology</i> , 2019, 130, 131-141.	2.5	15
97	Useful Predictors of Outcome in Methadone-Treated Patients. <i>Journal of Maintenance in the Addictions</i> , 1998, 1, 15-28.	0.1	15
98	Comparative Safety and Side Effect Profiles of Buprenorphine and Methadone in the Outpatient Treatment of Opioid Dependence. <i>Addictive Disorders and Their Treatment</i> , 2005, 4, 49-64.	0.5	14
99	Behavioural health interventions in the Johns Hopkins Community Health Partnership: Integrated care as a component of health systems transformation. <i>International Review of Psychiatry</i> , 2014, 26, 648-656.	2.8	13
100	Differential adoption of opioid agonist treatments in detoxification and outpatient settings. <i>Journal of Substance Abuse Treatment</i> , 2019, 107, 24-28.	2.8	13
101	Integrated dual diagnosis treatment among United States mental health treatment facilities: 2010 to 2018. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108074.	3.2	12
102	To take or not to take: the association between perceived addiction risk, expected analgesic response and likelihood of trying novel pain relievers in self-identified chronic pain patients. <i>Addiction</i> , 2018, 113, 67-79.	3.3	11
103	Trends in first-time treatment admissions for older adults with alcohol use disorder: Availability of medical and specialty clinical services in hospital, residential, and outpatient facilities. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107694.	3.2	11
104	Comparison of cognitive performance in methadone maintenance patients with and without current cocaine dependence. <i>Drug and Alcohol Dependence</i> , 2012, 124, 167-171.	3.2	10
105	Effects of methadone plus alcohol on cognitive performance in methadone-maintained volunteers. <i>American Journal of Drug and Alcohol Abuse</i> , 2015, 41, 251-256.	2.1	10
106	A preliminary examination of the multiple dimensions of opioid craving. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108473.	3.2	10
107	Outpatient treatment entry and health care utilization after a combined medical/substance abuse intervention for hospitalized medical patients. <i>Journal of General Internal Medicine</i> , 2002, 17, 334-340.	2.6	9
108	The Effect of Repeated Intramuscular Alfentanil Injections on Experimental Pain and Abuse Liability Indices in Healthy Males. <i>Clinical Journal of Pain</i> , 2014, 30, 36-45.	1.9	9



#	ARTICLE	IF	CITATIONS
109	Registered Reports: A new submission format at Drug and Alcohol Dependence. Drug and Alcohol Dependence, 2014, 137, 1-2.	3.2	8
110	Differences in patient-reported and observer-rated opioid withdrawal symptom etiology, time course, and relationship to clinical outcome. Drug and Alcohol Dependence, 2020, 215, 108212.	3.2	8
111	Electronic health record adoption among US substance use disorder and other mental health treatment facilities. Drug and Alcohol Dependence, 2021, 220, 108515.	3.2	8
112	If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics. Journal of Pain, 2022, 23, 1666-1679.	1.4	8
113	The Relationship between Antidepressant Use and Smoking Cessation in Pregnant Women in Treatment for Substance Abuse. American Journal of Drug and Alcohol Abuse, 2010, 36, 46-51.	2.1	7
114	Effects of oral caffeine pretreatment on response to intravenous nicotine and cocaine.. Experimental and Clinical Psychopharmacology, 2010, 18, 305-315.	1.8	7
115	Topiramate impairs cognitive function in methadone-maintained individuals with concurrent cocaine dependence.. Psychology of Addictive Behaviors, 2015, 29, 237-246.	2.1	7
116	Continuous Abstinence During Early Alcohol Treatment is Significantly Associated with Positive Treatment Outcomes, Independent of Duration of Abstinence. Alcohol and Alcoholism, 2017, 52, 72-79.	1.6	7
117	Sex and Age Differences in Risk Factors of Marijuana Involvement During Adolescence. Addictive Disorders and Their Treatment, 2018, 17, 29-39.	0.5	7
118	Hegemony, homogeneity, and DSM-5 SUD. Drug and Alcohol Dependence, 2021, 221, 108660.	3.2	7
119	Wireless electroencephalography (EEG) to monitor sleep among patients being withdrawn from opioids: Evidence of feasibility and utility.. Experimental and Clinical Psychopharmacology, 2022, 30, 1016-1023.	1.8	7
120	The Effects of Cocaine in Buprenorphine-Maintained Outpatient Volunteers:Results from Clinical Experience and Laboratory Challenges. American Journal on Addictions, 1994, 3, 129-143.	1.4	6
121	Opioid abusersâ€™ ability to differentiate an opioid from placebo in laboratory challenge testing. Drug and Alcohol Dependence, 2013, 132, 369-372.	3.2	5
122	Initial feasibility and validity of a prospective memory training program in a substance use treatment population.. Experimental and Clinical Psychopharmacology, 2016, 24, 390-399.	1.8	5
123	The relationship between pupil diameter and other measures of opioid withdrawal during naloxone precipitated withdrawal. Drug and Alcohol Dependence, 2019, 202, 111-114.	3.2	5
124	A Randomized and Controlled Acceptability Trial of an Internet-based Therapy among Inpatients with Co-occurring Substance Use and Other Psychiatric Disorders. Journal of Dual Diagnosis, 2020, 16, 447-454.	1.2	5
125	Moving Beyond Medications That Act at the Î¼ Receptor in the Treatment of Opioid Use Disorder. JAMA Psychiatry, 2021, 78, 701.	11.0	5
126	Single versus multiple drug focus in substance abuse clinical trials research: the devil is in the details. Drug and Alcohol Dependence, 2003, 70, 131-134.	3.2	4



#	ARTICLE	IF	CITATIONS
127	Recruitment Techniques for Alcohol Pharmacotherapy Clinical Trials. <i>Addictive Disorders and Their Treatment</i> , 2015, 14, 211-219.	0.5	4
128	Age and Gender Considerations for Technology-assisted Delivery of Therapy for Substance Use Disorder Treatment: A Patient Survey of Access to Electronic Devices. <i>Addictive Disorders and Their Treatment</i> , 2016, 15, 149-156.	0.5	4
129	Medical Devices to Prevent Opioid Use Disorder. <i>JAMA Psychiatry</i> , 2019, 76, 351.	11.0	4
130	Drug Legalization and Decriminalization Beliefs Among Substance-using and Nonusing Individuals. <i>Journal of Addiction Medicine</i> , 2020, 14, 56-62.	2.6	4
131	Meaning and purpose in the context of opioid overdose deaths. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108528.	3.2	4
132	Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone. <i>Drug and Alcohol Dependence</i> , 2021, 226, 108869.	3.2	4
133	Characterization of basal ganglia volume changes in the context of HIV and polysubstance use. <i>Scientific Reports</i> , 2022, 12, 4357.	3.3	4
134	Differences at Treatment Entry Between Opioid-Dependent and Cocaine-Dependent Males and Females. <i>Addictive Disorders and Their Treatment</i> , 2004, 3, 110-121.	0.5	3
135	Screening for Mood Disorder in Pregnant Substance-dependent Patients. <i>Addictive Disorders and Their Treatment</i> , 2009, 8, 88-98.	0.5	3
136	News and social media coverage is associated with more downloads and citations of manuscripts that focus on substance use. <i>Drug and Alcohol Dependence</i> , 2021, 218, 108357.	3.2	3
137	Familial perceptions of appropriate treatment types and goals for a family member who has opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108649.	3.2	3
138	Provider Continuity in the Prescribing of Buprenorphine/Naloxone Within Medicare Part D. <i>Journal of Addiction Medicine</i> , 2021, 15, 325-333.	2.6	3
139	Objective sleep outcomes in randomized-controlled trials in persons with substance use disorders: A systematic review. <i>Drug and Alcohol Dependence</i> , 2022, , 109509.	3.2	3
140	Comparison of demographic and clinical characteristics between opioid-dependent individuals admitted to a community-based treatment setting and those enrolled in a research-based treatment setting. <i>Journal of Substance Abuse Treatment</i> , 2007, 33, 355-361.	2.8	2
141	Experimentally-Induced Spontaneous Opiate Withdrawal: Relationship to Cigarette Craving and Expired Air Carbon Monoxide. <i>American Journal on Addictions</i> , 2007, 16, 310-315.	1.4	2
142	Drug use and sport – A commentary on: Injury, pain and prescription opioid use among former National Football League football players by Cottler et al.. <i>Drug and Alcohol Dependence</i> , 2011, 116, 8-10.	3.2	2
143	Response to commentaries: The quest(ion) remains in the search for a meaningful reduction – based endpoint. <i>Addiction</i> , 2019, 114, 21-23.	3.3	1
144	Dose-Related Efficacy of Levomethadyl Acetate for Treatment of Opioid Dependence. <i>Survey of Anesthesiology</i> , 1998, 42, 98.	0.1	0

#	ARTICLE	IF	CITATIONS
145	Review: there is insufficient evidence for naltrexone maintenance treatment in opioid dependence. Evidence-Based Mental Health, 2003, 6, 57-57.	4.5	0
146	Changes at Drug and Alcohol Dependence. Drug and Alcohol Dependence, 2010, 111, 3-3.	3.2	0
147	Response to "Commercial Factors Override Science in Combination Addiction Drug Trial" Clinical Pharmacology and Therapeutics, 2011, 90, 650-650.	4.7	0
148	Introduction. Drug and Alcohol Dependence, 2015, 156, e1.	3.2	0
149	Drug and Alcohol Dependence Fellowship. Drug and Alcohol Dependence, 2015, 153, 1.	3.2	0
150	A new Associate Editor for Drug and Alcohol Dependence: Dr. Adam Leventhal. Drug and Alcohol Dependence, 2016, 160, 1.	3.2	0
151	Introduction to CPDD abstracts from the 2016 conference. Drug and Alcohol Dependence, 2017, 171, e1.	3.2	0
152	Tramadol Extended-Release and Opioid Withdrawal Management"Legal Implications"Reply. JAMA Psychiatry, 2018, 75, 215.	11.0	0
153	Symptom severity and medication-assisted treatment for individuals with serious mental illness and a history of heroin use. Psychiatry Research, 2021, 296, 113671.	3.3	0
154	The defining characteristic of substance use disorders. Drug and Alcohol Dependence, 2022, 230, 109207.	3.2	0
155	Fare well. Drug and Alcohol Dependence, 2022, 231, 109264.	3.2	0
156	A comparison of registered and published primary outcomes in clinical trials of opioid use disorder: ACTION review and recommendations. Drug and Alcohol Dependence, 2022, 236, 109447.	3.2	0
157	P331. Meta-Analysis of Functional Imaging Studies of Acute Administration of Psychedelics. Biological Psychiatry, 2022, 91, S221.	1.3	0